Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan + capecitabine + bevacizumab as first-line therapy for advanced colorectal cancer
ChiCTR2500103252Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2025
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan in colorectal adenocarcinoma and colorectal cancer (CRC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate (ORR). Planned start May 2025; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500103252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103252.